Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients
Information source: Merck
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: valsartan (Drug); pravastatin (Drug); simvastatin (Drug); ezetimibe (+) simvastatin (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
Evaluate pleiotropic effects of simvastatin in hypertensive patients.
Clinical Details
Official title: Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Left ventricular mass reduction.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Females Or Males Over 18 Years Old
- Patients With Systemic Arterial Hypertension Grade I And Ii According With The
European Society Of Cardiology
- Left Ventricular hypertrophy Demonstrated By Echocardiography
- Mild To Moderated hypercholesterolemia
- Willing To Participate And Sign The Informed Consent Form (ICF)
Exclusion Criteria:
- Type 1 Or 2 Diabetes Mellitus
- Familiar hypercholesterolemia
- C-LDL > 190 Mg/Dl
- History Of Myocardial Infarction Or Stable Chronic Angina
- Triglycerides >250 Mg/Dl
Locations and Contacts
Merck Sharp & Dohme De Mexico, S.A. De C.V., Mexico, D.F. 1090, Mexico; Recruiting
Juan Diaz, Phone: 52-55-5481-9825
Additional Information
Starting date: July 2008
Last updated: January 8, 2009
|
